JP7306829B2 - 転移性癌の診断及び治療の方法 - Google Patents

転移性癌の診断及び治療の方法 Download PDF

Info

Publication number
JP7306829B2
JP7306829B2 JP2018566415A JP2018566415A JP7306829B2 JP 7306829 B2 JP7306829 B2 JP 7306829B2 JP 2018566415 A JP2018566415 A JP 2018566415A JP 2018566415 A JP2018566415 A JP 2018566415A JP 7306829 B2 JP7306829 B2 JP 7306829B2
Authority
JP
Japan
Prior art keywords
cells
gene
cancer
cell
kif3b
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018566415A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2017214726A5 (https=
JP2019525903A5 (https=
JP2019525903A (ja
Inventor
ルイス、ジョン
ストレトフ、コンスタンティン
ウィレッツ、リアン
Original Assignee
エントス ファーマシューティカルズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エントス ファーマシューティカルズ インコーポレイテッド filed Critical エントス ファーマシューティカルズ インコーポレイテッド
Publication of JP2019525903A publication Critical patent/JP2019525903A/ja
Publication of JPWO2017214726A5 publication Critical patent/JPWO2017214726A5/ja
Publication of JP2019525903A5 publication Critical patent/JP2019525903A5/ja
Priority to JP2023107289A priority Critical patent/JP2023123748A/ja
Application granted granted Critical
Publication of JP7306829B2 publication Critical patent/JP7306829B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2018566415A 2016-06-14 2017-06-14 転移性癌の診断及び治療の方法 Active JP7306829B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023107289A JP2023123748A (ja) 2016-06-14 2023-06-29 転移性癌の診断及び治療の方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CA2932910A CA2932910A1 (en) 2016-06-14 2016-06-14 Methods for diagnosing and treating metastatic cancer
CA2,932,910 2016-06-14
PCT/CA2017/050729 WO2017214726A1 (en) 2016-06-14 2017-06-14 Methods for diagnosing and treating metastatic cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023107289A Division JP2023123748A (ja) 2016-06-14 2023-06-29 転移性癌の診断及び治療の方法

Publications (4)

Publication Number Publication Date
JP2019525903A JP2019525903A (ja) 2019-09-12
JPWO2017214726A5 JPWO2017214726A5 (https=) 2023-06-02
JP2019525903A5 JP2019525903A5 (https=) 2023-06-02
JP7306829B2 true JP7306829B2 (ja) 2023-07-11

Family

ID=60655897

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018566415A Active JP7306829B2 (ja) 2016-06-14 2017-06-14 転移性癌の診断及び治療の方法
JP2023107289A Pending JP2023123748A (ja) 2016-06-14 2023-06-29 転移性癌の診断及び治療の方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023107289A Pending JP2023123748A (ja) 2016-06-14 2023-06-29 転移性癌の診断及び治療の方法

Country Status (8)

Country Link
US (2) US11236331B2 (https=)
EP (1) EP3468564A4 (https=)
JP (2) JP7306829B2 (https=)
CN (1) CN109562121A (https=)
AU (2) AU2017285726B2 (https=)
CA (2) CA2932910A1 (https=)
MX (2) MX2018015474A (https=)
WO (1) WO2017214726A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11304988B2 (en) * 2018-01-24 2022-04-19 Northwestern University Inhibiting tumor cell migration by inhibition of kinesin light chain 1, variant 1 (KLC1C)
US20210251963A1 (en) * 2018-09-06 2021-08-19 Scandion Oncology A/S Urea derivatives for use in the treatment of subjects with elevated expression and/or activity of srpk1
CN117187375B (zh) * 2023-09-12 2024-06-18 上海谱希和光基因科技有限公司 Kdelr3生物标志物在诊断高度近视中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007026896A1 (ja) 2005-09-02 2007-03-08 Toray Industries, Inc. 腎ガン診断、腎ガン患者予後予測のための組成物および方法
WO2013098797A2 (en) 2011-12-31 2013-07-04 Kuriakose Moni Abraham Diagnostic tests for predicting prognosis, recurrence, resistance or sensitivity to therapy and metastatic status in cancer
WO2016002844A1 (ja) 2014-07-04 2016-01-07 国立大学法人高知大学 膵がん細胞浸潤転移阻害剤

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US6040166A (en) 1985-03-28 2000-03-21 Roche Molecular Systems, Inc. Kits for amplifying and detecting nucleic acid sequences, including a probe
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5116742A (en) 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
CA1340807C (en) 1988-02-24 1999-11-02 Lawrence T. Malek Nucleic acid amplification process
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
DE3938907C2 (de) 1989-11-24 1999-11-04 Dade Behring Marburg Gmbh Mittel zum Lagern und Suspendieren von Zellen, insbesondere Erythrozyten
FR2814349B1 (fr) 2000-09-27 2002-12-06 Salomon Sa Sac a dos
CN101300348A (zh) 2005-09-02 2008-11-05 东丽株式会社 肾癌诊断、肾癌患者预后预测用的组合物及方法
WO2007056604A2 (en) 2005-11-09 2007-05-18 Irm Llc Methods and compositions for modulating cell motility and inhibiting tumor metastasis
GB0724532D0 (en) 2007-12-17 2008-01-30 Nat Univ Ireland Trail variants for treating cancer
US20160025728A1 (en) 2013-03-15 2016-01-28 Board Of Regents, The University Of Texas System Brain-specific gene signature of tumor cells

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007026896A1 (ja) 2005-09-02 2007-03-08 Toray Industries, Inc. 腎ガン診断、腎ガン患者予後予測のための組成物および方法
WO2013098797A2 (en) 2011-12-31 2013-07-04 Kuriakose Moni Abraham Diagnostic tests for predicting prognosis, recurrence, resistance or sensitivity to therapy and metastatic status in cancer
WO2016002844A1 (ja) 2014-07-04 2016-01-07 国立大学法人高知大学 膵がん細胞浸潤転移阻害剤

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Dig.Dis.Sci.，2014年，Vol.59，pp.795-806

Also Published As

Publication number Publication date
WO2017214726A1 (en) 2017-12-21
JP2023123748A (ja) 2023-09-05
AU2017285726A1 (en) 2019-01-24
US11236331B2 (en) 2022-02-01
US12421514B2 (en) 2025-09-23
EP3468564A4 (en) 2020-07-29
AU2023203737B2 (en) 2024-08-29
CA2932910A1 (en) 2017-12-14
MX2018015474A (es) 2019-06-06
US20190177727A1 (en) 2019-06-13
EP3468564A1 (en) 2019-04-17
JP2019525903A (ja) 2019-09-12
AU2017285726B2 (en) 2023-03-16
CN109562121A (zh) 2019-04-02
CA3027430A1 (en) 2017-12-21
US20220112498A1 (en) 2022-04-14
AU2023203737A1 (en) 2023-07-06
MX2022012073A (es) 2022-10-18

Similar Documents

Publication Publication Date Title
US12060619B2 (en) Treatment of angiogenesis disorders
JP2023123748A (ja) 転移性癌の診断及び治療の方法
JP2019502664A (ja) 望ましくない細胞増殖に関係する疾患の処置のための薬剤
JP2016127833A (ja) 癌治療のための薬剤標的としてのＦｒａ−１標的遺伝子
JP2016101167A (ja) がん幹細胞を含むまたはそれに由来するがんの治療、予防および診断のための方法および組成物
JP5395246B2 (ja) 乳癌および卵巣癌の治療薬、検出方法ならびに検出用キット
Broderick et al. SCCRO promotes glioma formation and malignant progression in mice
US20160208335A1 (en) Use of RhoA in Cancer Diagnosis and Inhibitor Screening
CN114540490B (zh) Lcdr作为预防和/或治疗癌症的药物的治疗靶点中的应用
US8486905B2 (en) Use of FLJ25416 gene
JP6839707B2 (ja) Ｇｐｒ１６０を過剰発現する癌の予防、診断および治療
US20080096210A1 (en) Cancer suppressing agent
KR102727594B1 (ko) 육종의 진단 및 치료를 위한 tjp1의 용도
JP5704545B2 (ja) 甲状腺癌の検出方法
JP2010022236A (ja) 甲状腺癌の検出方法
KR20240139138A (ko) 항-egfr 치료에 대한 반응성 예측용 조성물
KR20200118931A (ko) 저산소 환경에서 유발되는 암의 전이 억제용 조성물

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200612

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200612

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210603

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210902

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211102

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211202

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220414

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220706

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220914

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221007

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221227

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230327

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230524

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20230524

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230531

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230629

R150 Certificate of patent or registration of utility model

Ref document number: 7306829

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150